EC Merger regulation (EUMR)
AI-assisted content notice: this page includes AI-assisted summaries, FAQs, and glossary entries prepared for navigation purposes. Verify the underlying legal text before relying on this content.
Summary
Council Regulation (EC) No 139/2004 (the EU Merger Regulation) establishes the EU system for reviewing concentrations (mergers, acquisitions and certain joint ventures) with an EU dimension. It sets out when transactions must be notified to the European Commission, the substantive test for compatibility with the internal market, and the Commission’s investigative and decision-making powers. It also governs cooperation and case allocation between the Commission and national competition authorities under the “one-stop shop” principle.
Who is affected?
Companies planning mergers, acquisitions or full-function joint ventures that meet the EU turnover thresholds are directly affected, as they may be required to notify and obtain clearance before closing. Legal and financial advisers, as well as competitors, customers and suppliers, are indirectly affected through the review process and potential remedies.
Scope
Applies to concentrations with an EU dimension, setting mandatory pre-notification and standstill obligations and a Commission-led assessment of their effects on competition in the internal market.
Key Points
- Defines “concentration” and the types of transactions covered (mergers, acquisitions of control, and full-function joint ventures).
- Establishes EU turnover thresholds for an “EU dimension” and mandatory notification to the European Commission.
- Imposes a standstill obligation (no implementation before clearance) and provides for sanctions for non-compliance.
- Sets the substantive assessment standard (significant impediment to effective competition, including through creation/strengthening of dominance).
- Provides procedural rules and timelines for Phase I and Phase II investigations, including commitments/remedies and rights of defence.
- Creates referral mechanisms between the Commission and Member States’ authorities (case allocation and cooperation).
Frequently Asked Questions
Who must comply with the EC Merger Regulation (EUMR)?
Companies involved in mergers, acquisitions, or the creation of full-function joint ventures that meet the EU turnover thresholds must comply with the EUMR. Legal and financial advisers, as well as other market participants, may also be affected during the review process.
What types of transactions fall under the scope of the EUMR?
The EUMR applies to 'concentrations,' which include mergers, acquisitions of control, and the creation of full-function joint ventures with an EU dimension as defined by specific turnover thresholds.
What are the key obligations for companies under the EUMR?
Companies must notify qualifying concentrations to the European Commission before implementation and must not close the transaction until clearance is granted (standstill obligation). They must also provide accurate information and cooperate with the Commission's investigation.
What are the penalties for non-compliance with the EUMR?
Non-compliance, such as failing to notify or implementing a concentration before clearance, can result in significant fines of up to 10% of the companies' aggregate turnover and possible invalidation of the transaction.
How does the notification process work under the EUMR?
Companies must submit a notification to the European Commission if their transaction meets the EU turnover thresholds. The Commission then assesses the concentration through a structured investigation process (Phase I and, if necessary, Phase II).
What is the substantive test for assessing concentrations under the EUMR?
The Commission evaluates whether the concentration would significantly impede effective competition in the internal market, in particular by creating or strengthening a dominant position.
How does the EUMR interact with national competition authorities?
The EUMR establishes referral mechanisms allowing cases to be transferred between the European Commission and national competition authorities to ensure efficient case allocation and avoid duplicate reviews.
What are the timelines for the Commission’s review under the EUMR?
Phase I investigations must be completed within 25 working days after notification, while Phase II (in-depth) investigations can take up to 90 additional working days, with possible extensions in certain circumstances.
What practical steps should companies take to ensure compliance with the EUMR?
Companies should assess whether their transaction meets the EU thresholds, prepare the required notification, refrain from implementing the deal before clearance, and engage with legal advisers to manage the process and any potential remedies.
Are there any exceptions or special referral procedures under the EUMR?
Yes, the EUMR provides for pre- and post-notification referral mechanisms, allowing either the Commission or Member States to request or relinquish jurisdiction over certain cases based on their impact on competition.
Key Terms
- Concentration
- A transaction resulting in a lasting change of control in one or more undertakings, including mergers, acquisitions, and full-function joint ventures.
- EU Dimension
- A threshold based on the combined turnover of the parties involved, determining whether a concentration must be notified to the European Commission.
- Standstill Obligation
- The requirement that parties to a notifiable concentration must not implement the transaction until the European Commission has granted clearance.
- Full-Function Joint Venture
- A joint venture performing all the functions of an autonomous economic entity on a lasting basis, subject to merger control under the EUMR.
- Significant Impediment to Effective Competition (SIEC) Test
- The substantive standard used by the Commission to assess whether a concentration would harm competition in the internal market.
- Phase I Investigation
- The initial review period (25 working days) during which the Commission determines if a concentration raises serious competition concerns.
- Phase II Investigation
- An in-depth investigation (up to 90 additional working days) conducted if Phase I raises concerns about the concentration's impact on competition.
- Referral Mechanism
- Procedures allowing cases to be transferred between the European Commission and national competition authorities for efficient case allocation.
- Commitments/Remedies
- Measures proposed by the parties to address competition concerns identified by the Commission, often as a condition for clearance.
- Control
- The possibility of exercising decisive influence over an undertaking, either through rights, contracts, or other means, central to defining a concentration.